IL119961A - Pneumococcal polysaccharide - immunogenic protein conjugate - Google Patents

Pneumococcal polysaccharide - immunogenic protein conjugate

Info

Publication number
IL119961A
IL119961A IL11996192A IL11996192A IL119961A IL 119961 A IL119961 A IL 119961A IL 11996192 A IL11996192 A IL 11996192A IL 11996192 A IL11996192 A IL 11996192A IL 119961 A IL119961 A IL 119961A
Authority
IL
Israel
Prior art keywords
pro
immune responses
conjugates
pneumococcal
protein conjugate
Prior art date
Application number
IL11996192A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27094961&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL119961(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of IL119961A publication Critical patent/IL119961A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
IL11996192A 1991-01-28 1992-01-21 Pneumococcal polysaccharide - immunogenic protein conjugate IL119961A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64657091A 1991-01-28 1991-01-28
US80794291A 1991-12-19 1991-12-19
IL10071692A IL100716A (en) 1991-01-28 1992-01-21 Vaccine of Pneumococcal Polysaccharide Conjugate

Publications (1)

Publication Number Publication Date
IL119961A true IL119961A (en) 2000-01-31

Family

ID=27094961

Family Applications (5)

Application Number Title Priority Date Filing Date
IL11996192A IL119961A (en) 1991-01-28 1992-01-21 Pneumococcal polysaccharide - immunogenic protein conjugate
IL10071692A IL100716A (en) 1991-01-28 1992-01-21 Vaccine of Pneumococcal Polysaccharide Conjugate
IL11996292A IL119962A (en) 1991-01-28 1992-01-21 Process for making a pneumococcal polysaccharide - immunogenic protein conjugate
IL11996197A IL119961A0 (en) 1991-01-28 1997-01-03 Pneumococcal polysaccharide-immunogenic protein conjugate
IL11996297A IL119962A0 (en) 1991-01-28 1997-01-03 Process for making a pneumococcal polysaccharide-immunogenic protein conjugate

Family Applications After (4)

Application Number Title Priority Date Filing Date
IL10071692A IL100716A (en) 1991-01-28 1992-01-21 Vaccine of Pneumococcal Polysaccharide Conjugate
IL11996292A IL119962A (en) 1991-01-28 1992-01-21 Process for making a pneumococcal polysaccharide - immunogenic protein conjugate
IL11996197A IL119961A0 (en) 1991-01-28 1997-01-03 Pneumococcal polysaccharide-immunogenic protein conjugate
IL11996297A IL119962A0 (en) 1991-01-28 1997-01-03 Process for making a pneumococcal polysaccharide-immunogenic protein conjugate

Country Status (23)

Country Link
US (1) US5623057A (xx)
EP (1) EP0497525B2 (xx)
JP (1) JPH0794472B2 (xx)
KR (1) KR100243958B1 (xx)
CN (1) CN1080124C (xx)
AT (1) ATE169825T1 (xx)
AU (1) AU651656B2 (xx)
CA (1) CA2059692C (xx)
CZ (1) CZ283284B6 (xx)
DE (1) DE69226668T3 (xx)
DK (1) DK0497525T4 (xx)
ES (1) ES2121820T5 (xx)
FI (1) FI107370B (xx)
HU (1) HU216101B (xx)
IE (1) IE920244A1 (xx)
IL (5) IL119961A (xx)
LV (1) LV12309B (xx)
MX (1) MX9200328A (xx)
NO (1) NO304117B1 (xx)
NZ (1) NZ241367A (xx)
SI (1) SI9210081B (xx)
SK (1) SK280659B6 (xx)
YU (1) YU49068B (xx)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
US5445817A (en) * 1992-08-21 1995-08-29 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5681570A (en) * 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
US5747287A (en) * 1995-04-28 1998-05-05 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5866132A (en) * 1995-06-07 1999-02-02 Alberta Research Council Immunogenic oligosaccharide compositions
AU725279B2 (en) * 1995-06-07 2000-10-12 Alberta Research Council Inc. Immunogenic and immunostimulatory oligosaccharide compositions and methods of making and using them
US5695768A (en) 1995-06-07 1997-12-09 Alberta Research Council Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
US6410025B1 (en) 1996-02-14 2002-06-25 Merck & Co., Inc. Polysaccharide precipitation process
SE9601158D0 (sv) * 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
ATE208629T1 (de) 1996-08-27 2001-11-15 Chiron Corp Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
EP0998557A2 (en) * 1997-07-21 2000-05-10 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
US6224880B1 (en) 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
US6756361B1 (en) * 1997-10-14 2004-06-29 Nabi Enterococcus antigens and vaccines
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
AU759391B2 (en) * 1998-02-12 2003-04-10 Wyeth Holdings Corporation Pneumococcal and meningococcal vaccines formulated with interleukin-12
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
AU760669B2 (en) * 1998-04-28 2003-05-22 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
GB9816337D0 (en) * 1998-07-27 1998-09-23 Cortecs Uk Ltd Proteins
US6824997B1 (en) * 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
US20080096236A1 (en) * 1998-08-25 2008-04-24 Binax, Inc. Method for Detecting the Presence of Target Bacteria or a Target Component Carbohydrate Antigen Thereof
US9134303B1 (en) 1998-08-25 2015-09-15 Alere Scarborough, Inc. ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto
US6146902A (en) * 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
GB9906437D0 (en) * 1999-03-19 1999-05-12 Smithkline Beecham Biolog Vaccine
MY125202A (en) * 1999-03-19 2006-07-31 Smithkline Beecham Biologicals S A Vaccine
US20040191834A1 (en) * 1999-10-28 2004-09-30 Laferriere Craig Antony Joseph Novel method
JP4870895B2 (ja) * 2000-06-29 2012-02-08 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン組成物
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
EP1569955A2 (en) * 2002-12-03 2005-09-07 Sloan-Kettering Institute For Cancer Research Gp120 specific antigens, conjugates thereof, methods for their preparation and uses thereof
US7369578B2 (en) * 2003-07-01 2008-05-06 Nortel Networks Limited Digital processing of SONET pointers
MY144231A (en) * 2003-12-17 2011-08-15 Wyeth Corp Aß IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME
EA012984B1 (ru) * 2003-12-17 2010-02-26 Вайет Конъюгаты иммуногенных пептидных носителей и способы их получения
ES2540770T3 (es) 2004-09-22 2015-07-13 Glaxosmithkline Biologicals Sa Composición inmunógena para uso en vacunación contra estafilococos
IL308456A (en) 2005-04-08 2024-01-01 Wyeth Llc A multivalent pneumomuroral protein-polysaccharide conjugate preparation
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2011253684B8 (en) * 2005-04-08 2013-07-11 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US8329184B2 (en) 2005-06-27 2012-12-11 Glaxosmithkline Biologicals S.A. Process for manufacturing vaccines
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
PT1962899E (pt) 2005-12-22 2011-10-19 Glaxosmithkline Biolog Sa Vacina conjugada polissacarídica pneumocócica
GB0607088D0 (en) * 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
CN101024079B (zh) * 2006-02-17 2012-02-01 福州昌晖生物工程有限公司 肺炎链球菌多糖-外膜蛋白结合疫苗及制备方法
EA020459B1 (ru) 2006-03-30 2014-11-28 Глаксосмитклайн Байолоджикалс С.А. Иммуногенная композиция
AU2013200552B9 (en) * 2006-04-07 2014-07-03 Glaxosmithkline Biologicals S.A. Conjugate vaccines
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
ZA200900899B (en) * 2006-08-07 2010-07-28 Harvard College Protein matrix vaccines and methods of making and administering such vaccines
EA016417B1 (ru) 2006-09-07 2012-04-30 Глаксосмитклайн Байолоджикалс С.А. Способ получения вакцины
AU2007307800C1 (en) * 2006-10-10 2014-03-13 Wyeth Llc Purification of Streptococcus pneumoniae type 3 polysaccharides
CN1963500B (zh) * 2006-12-06 2010-05-12 云南沃森生物技术股份有限公司 一种肺炎链球菌荚膜多糖结合物中游离多糖含量的测定方法
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
EP2436700B8 (en) * 2007-03-23 2018-08-01 Wyeth LLC Shortened purification process for the production of capsular streptococcus pneumoniae polysaccharides
WO2008129559A2 (en) 2007-04-23 2008-10-30 Serum Institute Of India Ltd Antigenic polysaccharides and process for their preparation
AR066376A1 (es) 2007-05-02 2009-08-12 Glaxosmithkline Biolog Sa Vacuna
BRPI0813644B8 (pt) 2007-06-26 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, processo para fabricar a mesma, e, uso da composição imunogênica ou vacina
CN102333540B (zh) 2008-10-06 2015-04-22 芝加哥大学 与细菌eap、emp和/或adsa蛋白相关的组合物和方法
SI2379734T1 (en) * 2008-12-18 2018-05-31 Wyeth Llc PROCEDURE FOR THE CONTROL OF THE SEROTYPE 19A STREPTOCOCCUS PNEUMONIAE POLYESAHARIDE MOLECULAR MASS
PL2385981T3 (pl) * 2008-12-18 2020-01-31 Wyeth Llc Sposób kontroli masy cząsteczkowej polisacharydów streptococcus pneumoniae z zastosowaniem węgla
WO2010083477A2 (en) 2009-01-16 2010-07-22 University Of Maryland, Baltimore Broad spectrum vaccine against non-typhoidal salmonella
ES2784957T3 (es) 2009-04-03 2020-10-02 Univ Chicago Composiciones y métodos relacionados con variantes de la proteína A (SPA)
US20120135037A1 (en) 2009-06-01 2012-05-31 Mizel Steven B Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
IN2012DN00791A (xx) * 2009-06-29 2015-06-26 Genocea Biosciences Inc
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
EP2555794A4 (en) 2010-04-05 2014-01-15 Univ Chicago PROTEIN A (SPA) ANTIBODY COMPOSITIONS AND METHODS AS AN IMMUNE RESPONSE AMPLIFIER
WO2011148382A1 (en) 2010-05-28 2011-12-01 Biological E Limited An improved process for the purification of capsular polysaccharides of haemophilus influenza - b, neisseria meningitis such as serotypes a, c, y and w-135, and other similar related capsular polysaccharides produced from both gram negative and gram positive microorganisms using aluminium phosphate with alcohol.
JP6002128B2 (ja) 2010-07-02 2016-10-05 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ プロテインＡ（ＳｐＡ）変種に関連する組成物および方法
JP5793194B2 (ja) 2010-09-09 2015-10-14 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 感染防御ブドウ球菌抗原が関与する方法および組成物
RU2623174C2 (ru) 2011-01-20 2017-06-22 Дженоцея Байосайенсиз, Инк. Вакцины и композиции против streptococcus pneumoniae
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
US9878029B2 (en) 2011-03-22 2018-01-30 Serum Institute Of India Private Limited Process for preparation of polysaccharides
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
DK2788023T3 (en) 2011-12-06 2016-12-19 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
JP6379041B2 (ja) 2012-01-20 2018-08-22 ジェノセア バイオサイエンシーズ， インコーポレイテッド ストレプトコッカス・ニューモニエ（Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ）に対する融合抗原ワクチンおよび組成物
US9968668B2 (en) 2012-04-26 2018-05-15 The University Of Chicago Staphylococcal coagulase antigens and methods of their use
ITMI20121597A1 (it) * 2012-09-25 2014-03-26 Beta Pharma S A Coniugato tra frammento di parete cellulare batterica ed un veicolo mucopolisaccaridico e suoi usi in ambito medico
US11576958B2 (en) 2013-02-07 2023-02-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
CN105492454B (zh) * 2013-07-07 2019-09-27 马普科技促进协会 合成针对1型肺炎链球菌的疫苗
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2015110941A2 (en) * 2014-01-21 2015-07-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PT3096786T (pt) * 2014-01-21 2021-08-24 Pfizer Polissacáridos capsulares de streptococcus pneumoniae e conjugados dos mesmos
JP2017505792A (ja) * 2014-02-14 2017-02-23 ファイザー・インク 免疫原性糖タンパク質コンジュゲート
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
US10729780B2 (en) * 2015-06-08 2020-08-04 Serum Institute Of India Private Ltd. Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof
US11058757B2 (en) 2016-03-31 2021-07-13 Pogona, LLC Saccharide-polypeptide conjugate compositions and methods of use thereof
EP3269385A1 (en) 2016-07-12 2018-01-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Pneumococcal polysaccharide-protein conjugate composition
EP3474890A1 (en) 2016-06-22 2019-05-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften E. V. Pneumococcal polysaccharide-protein conjugate composition
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
WO2018144438A1 (en) 2017-01-31 2018-08-09 Merck Sharp & Dohme Corp. Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
WO2018144799A1 (en) 2017-02-03 2018-08-09 SCHADECK, Eva, Barbara Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof
US11400162B2 (en) 2017-02-24 2022-08-02 Merck Sharp & Dohme Llc Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
EP3585427A4 (en) * 2017-02-24 2020-12-30 Merck Sharp & Dohme Corp. METHODS FOR IMPROVING THE FILTRABILITY OF POLYSACCHARIDE CONJUGATE WITH PROTEIN REACTIONS
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
KR102634811B1 (ko) 2017-06-10 2024-02-06 인벤트프라이즈 인크. 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
US11524076B2 (en) 2017-09-07 2022-12-13 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
JP7293201B2 (ja) 2017-09-07 2023-06-19 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎球菌多糖体および免疫原性多糖体－キャリアタンパク質コンジュゲートでのその使用
AU2018328036B2 (en) 2017-09-07 2024-03-07 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
CN111093650B (zh) 2017-09-07 2024-03-01 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
MX2020002556A (es) 2017-09-07 2020-07-13 Merck Sharp & Dohme Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
CN117982633A (zh) 2017-12-06 2024-05-07 默沙东有限责任公司 包含肺炎链球菌多糖蛋白缀合物的组合物及其使用方法
CN108079286B (zh) * 2018-01-19 2020-07-31 云南沃森生物技术股份有限公司 一种13价肺炎球菌多糖-蛋白结合物组合物及其制备方法和应用
US11530432B2 (en) 2018-03-19 2022-12-20 Northwestern University Compositions and methods for rapid in vitro synthesis of bioconjugate vaccines in vitro via production and N-glycosylation of protein carriers in detoxified prokaryotic cell lysates
SG11202106541WA (en) 2018-12-19 2021-07-29 Merck Sharp & Dohme Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
US20220211859A1 (en) 2019-05-10 2022-07-07 Glaxosmithkline Biologicals Sa Conjugate production
US20220387614A1 (en) 2019-11-22 2022-12-08 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
EP3900739A1 (en) 2020-04-21 2021-10-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein
EP3919076A1 (en) 2020-06-02 2021-12-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetic oligosaccharide vaccines against streptococcus pneumoniae with microparticle adjuvant formulations
WO2021250626A2 (en) 2020-06-12 2021-12-16 Glaxosmithkline Biologicals Sa Dock tag system
TW202245835A (zh) 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
EP4297776A1 (en) 2021-02-26 2024-01-03 Biological E Limited Activated-quenched polysaccharide and improved methods for quantification of polysaccharide in a vaccine composition
EP4169513A1 (en) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising sting agonists
WO2024062494A1 (en) 2022-09-19 2024-03-28 Biological E Limited Method for the purification of capsular polysaccharides

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4324887A (en) * 1978-08-16 1982-04-13 President And Fellows Of Harvard College Type II group B Streptococci polysaccharide
US4221906A (en) * 1979-03-19 1980-09-09 American Cyanamid Company Stabilization of pneumococcal polysaccharides
US4242501A (en) * 1979-08-08 1980-12-30 American Cyanamid Company Purification of pneumococcal capsular polysaccharides
US4271147A (en) * 1980-01-10 1981-06-02 Behringwerke Aktiengesellschaft Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same
IE51174B1 (en) * 1980-04-14 1986-10-29 Merck & Co Inc Group b streptococcal capsular polysaccharides
FR2495939B1 (fr) * 1980-12-11 1985-10-11 Merieux Inst Procede de purification de polyosides de streptococcus pneumoniae et vaccin a base de polyosides ainsi purifies
NL8202527A (nl) * 1982-06-22 1984-01-16 Univ Utrecht Vaccins tegen door bacterien met kapsel-polysacchariden verwekte ziekten en werkwijze voor het bereiden daarvan.
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4644059A (en) * 1982-07-06 1987-02-17 Connaught Laboratories, Inc. Haemophilus influenzae B polysaccharide-diptheria toxoid conjugate vaccine
US4459286A (en) * 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4686102A (en) * 1984-04-12 1987-08-11 American Cyanamid Company Multivalent pneumococcal vaccine and preparation thereof
US4882317A (en) * 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
IT1187753B (it) * 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
ES2000034A6 (es) * 1985-11-26 1987-10-01 Schweiz Serum & Impfinst Procedimiento para la preparacion de una vacuna viva contra paperas
US4755381A (en) * 1986-03-27 1988-07-05 Swiss Serum And Vaccine Institute Berne Klebsiella capsular polysaccharide vaccine
EP0302887B1 (en) * 1986-04-16 1994-06-22 The Brigham And Women's Hospital, Inc. Bacterial antigens, antibodies, vaccines, and methods of manufacture
NZ223009A (en) * 1986-12-31 1990-06-26 Nl Rivm Of Thoven Oligosaccharides containing d-ribose d-ribitol and phosphate units mimicing haemophilus influenzae type b antigens
DE68915046T2 (de) * 1988-04-19 1994-12-08 American Cyanamid Co Haemophilus influenzae Typ B Polysaccharid-Aussermembranprotein-Konjugat als Impfstoff.
US5091300A (en) * 1989-08-03 1992-02-25 Merck & Co., Inc. Radio-immuno assay for hepatitis b virus pres2 antibodies
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
JP2636128B2 (ja) * 1993-02-03 1997-07-30 株式会社アマダメトレックス パンチング金型

Also Published As

Publication number Publication date
FI920353A0 (fi) 1992-01-27
NZ241367A (en) 1994-04-27
EP0497525B1 (en) 1998-08-19
JPH0794472B2 (ja) 1995-10-11
CA2059692A1 (en) 1992-07-29
MX9200328A (es) 1992-09-01
NO920350D0 (no) 1992-01-27
AU1046792A (en) 1992-07-30
JPH0565300A (ja) 1993-03-19
ES2121820T5 (es) 2010-05-28
EP0497525A3 (en) 1993-03-10
CS19992A3 (en) 1992-10-14
CN1080124C (zh) 2002-03-06
FI107370B (fi) 2001-07-31
LV12309A (lv) 1999-07-20
DK0497525T4 (da) 2010-07-05
IL119962A0 (en) 1997-04-15
IL119961A0 (en) 1997-04-15
EP0497525B2 (en) 2010-03-03
YU49068B (sh) 2003-08-29
HU216101B (hu) 1999-04-28
SI9210081B (en) 2001-12-31
HUT69968A (en) 1995-09-28
LV12309B (en) 1999-11-20
IL100716A (en) 1999-12-22
CN1064217A (zh) 1992-09-09
US5623057A (en) 1997-04-22
CA2059692C (en) 2004-11-16
SI9210081A (en) 1996-02-29
EP0497525A2 (en) 1992-08-05
NO920350L (no) 1992-07-29
ES2121820T3 (es) 1998-12-16
SK280659B6 (sk) 2000-05-16
KR100243958B1 (ko) 2000-02-01
IL100716A0 (en) 1992-09-06
YU8192A (sh) 1994-12-28
DK0497525T3 (da) 1998-10-26
CZ283284B6 (cs) 1998-02-18
KR920014829A (ko) 1992-08-25
DE69226668T3 (de) 2010-12-16
AU651656B2 (en) 1994-07-28
DE69226668T2 (de) 1999-04-22
IE920244A1 (en) 1992-07-29
DE69226668D1 (de) 1998-09-24
HU9200252D0 (en) 1992-04-28
ATE169825T1 (de) 1998-09-15
FI920353A (fi) 1992-07-29
NO304117B1 (no) 1998-10-26
IL119962A (en) 2000-01-31

Similar Documents

Publication Publication Date Title
IL119961A0 (en) Pneumococcal polysaccharide-immunogenic protein conjugate
LU90808I2 (fr) Conjugue serotype 18c d'oligosaccharide pneumococcique
KR920003982A (ko) 면역원성 콘쥬게이트 및 이를 함유하는 백신 조성물
FI964189A (fi) Immunogeeniset ryhmä A-streptokokkaaliset polysakkaridikoostumukset ja menetelmät
LU91595I2 (fr) Combinaison d'anatoxine diphtérique, d'anatoxine tétanique, d'anatoxine coquelucheuse, d'hémagglutinine filamenteuse, de pertactine et de polyoside capsulaire d'haemophilus influenzae type b (InfanrixHib)
HUP9801223A2 (hu) Eljárás specifikus antigénekre adott antitest válasz fokozására interleukin-10-zel
DE69333402D1 (en) Impfstoff beinhaltend bacterin und toxoid aus pasteurella haemolytica typ a-1

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired